Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
QuintilesIMS
McKinsey
Teva
Mallinckrodt
Fish and Richardson
UBS
US Department of Justice
McKesson

Generated: January 19, 2018

DrugPatentWatch Database Preview

SAIZEN Drug Profile

« Back to Dashboard

When do Saizen patents expire, and when can generic versions of Saizen launch?

Saizen is a drug marketed by Emd Serono and is included in one NDA.

The generic ingredient in SAIZEN is somatropin recombinant. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the somatropin recombinant profile page.

US Patents and Regulatory Information for SAIZEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono SAIZEN somatropin recombinant INJECTABLE;INJECTION 019764-005 Jan 16, 2007 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Emd Serono SAIZEN somatropin recombinant INJECTABLE;INJECTION 019764-003 Aug 29, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Emd Serono SAIZEN somatropin recombinant INJECTABLE;INJECTION 019764-002 Oct 8, 1996 BX RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Emd Serono SAIZEN somatropin recombinant INJECTABLE;INJECTION 019764-001 Oct 8, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SAIZEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono SAIZEN somatropin recombinant INJECTABLE;INJECTION 019764-002 Oct 8, 1996 ➤ Subscribe ➤ Subscribe
Emd Serono SAIZEN somatropin recombinant INJECTABLE;INJECTION 019764-003 Aug 29, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Dow
Argus Health
Boehringer Ingelheim
Baxter
Colorcon
Deloitte
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot